In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioMotiv LLC

www.biomotiv.com

Latest From BioMotiv LLC

Scrip Asks… What's The Current Climate For Deal-Making? (Part 2)

Following Gilead's acquisition of Kite, buzz grew that the deal might catalyze a surge in deal-making. Scrip asked a broad cross-section of biopharma insiders and observers about the deal-making environment – featured here are big pharma and industry experts.

Business Strategies M & A

OptiKira Pursuing A Novel Small-Molecule Approach To Retinitis Pigmentosa

An early-stage, small-molecule approach to the treatment of retinitis pigmentosa being developed by US biotech OptiKira may have potential benefits over more advanced gene and cell therapies for the blindness-causing condition.

Market Intelligence Ophthalmic

Deals Shaping The Medical Industry, October 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical Tools – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2015.

BioPharmaceutical Medical Device

Deal Watch: Genzyme Validates Alnylam's Strategy By Partnering On Hemophilia Candidate

Astellas/Chromocell pain therapy collaboration centers on New Jersey biotech's platform technology, which may solve the problem of reproducing Nav1.7 receptors for in vitro assays. Xoma signs preclinical immuno-oncology partnership with Novartis, dimming the focus on Phase III flop for gevokizumab.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • BioMotiv LLC
  • Senior Management
  • Baiju R Shah, CEO
    Ted Torphy, PhD, CSO
    Terry Vance, CBO
    Fares Zaboura, Fin. Mgr.
    Kaushik Ghosal, PhD, Bus. Dev. Mgr.
  • Contact Info
  • BioMotiv LLC
    Phone: (216) 455-3200
    20600 Chagrin Blvd.
    Ste. 210
    Cleveland, OH 44122
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register